Navigation Links
Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
Date:7/29/2013

PALO ALTO, Calif., July 29, 2013 /PRNewswire/ --  Signature Therapeutics, Inc., a development-stage biopharmaceutical company, announced today that it has received no-cost access to contractor resources through the National Center for Advancing Translational Sciences' Bridging Interventional Development Gaps (BrIDGs) program (part of the NIH) to support development of its extended-release, abuse-deterrent oxycodone, PF614 – a novel, inactive prodrug formulation that must be digested to achieve therapeutic benefit.  NIH's National Institute on Drug Abuse is providing funding directly to BrIDGs to support the project, which includes scale-up synthesis, drug product packaging, pharmacokinetic analysis and IND-enabling toxicology studies.

(Logo:  http://photos.prnewswire.com/prnh/20130729/SF54809LOGO)

Wes Sterman, President and CEO of Signature Therapeutics, commented, "We are grateful to the staff of NIDA and NCATS that saw the value of our abuse-deterrent prodrug technology and which made the decision to provide contractor resources to further our work.  Their support helps validate the importance of the prodrug technology approach in the field of abuse-deterrent opioid drugs, and the potential of the technology to greatly impact the public health crisis of prescription drug abuse.  We look forward to the continued development of PF614, and anticipate the filing of a US IND in the first half of 2014."

About Prescription Drug Abuse

Abuse of prescription drugs is the fastest growing drug problem according to the US Office of National Drug Control Policy (ONDCP).1   The Centers for Disease Control (CDC) has characterized this problem as an epidemic in the United States.2  More Americans die from overdose of prescription pain killers than from abuse of heroin and cocaine combined, reaching approximately 17,000 deaths per year.3,4  The healthcare costs of prescription drug abuse exceed $72 billion per year in the US.5 

About PF614

PF614 is a prodrug of the opioid drug oxycodone that is designed to create substantial hurdles to both oral and non-oral routes of abuse.  Typical methods of abuse of prescription opioid drugs include inhaling or injecting crushed pills or chewing intact pills.  Current efforts to thwart these modes of abuse, involving improved tablet-formulation technology to make tablets harder to crush and the opioid drug harder to remove from the tablet, provide some increased level of abuse-resistance.  However, Signature Therapeutics' prodrug technology involves creating new molecules that provide very high levels of abuse-resistance based upon the design of the molecules themselves.  PF614 is a novel molecule that is designed to release the opioid drug oxycodone only upon its digestion in the patient's small bowel.  It is essentially inert when inhaled or injected, resistant to chemical manipulation outside of the body, and completely resistant to release of oxycodone upon chewing. 

About Signature Therapeutics

Signature Therapeutics, Inc., is a development-stage biopharmaceutical company located in Palo Alto, California.  The Company focuses on the discovery and development of a portfolio of novel chemical entities for the potential treatment of neurological disorders. 

Signature Therapeutics Contact:
Wes Sterman, CEO
email:  wsterman@signaturerx.com 
phone:  650-331-4001
website:  http://www.signaturerx.com

1.  Epidemic: Responding to America's Prescription Drug Abuse Crisis, OFFICE OF NATIONAL DRUG CONTROL POLICY (2011), available at http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan_0.pdf.

2.  Leonard Paulozzi, et al., CDC Grand Rounds: Prescription Drug Overdoses—A U.S. Epidemic, CENTERS FOR DISEASE CONTROL AND PREVENTION, Jan. 13, 2012, available at  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3.htm.

3.  LEONARD PAULOZZI, supra Note 2.

4.  Press Release, Centers for Disease Control and Prevention, Opioids Drive Continued Increase in Drug Overdose Deaths (Feb. 20, 2013), available at http://www.cdc.gov/media/releases/2013/p0220_drug_overdose_deaths.html

5.  See Prescription Drug Abuse and Overdose: Public Health Perspective, CENTERS FOR DISEASE CONTROL AND PREVENTION, Oct. 24, 2012, available at http://www.cdc.gov/primarycare/materials/opoidabuse/docs/pda-phperspective-508.pdf.


'/>"/>
SOURCE Signature Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
2. CLAAD Lauds Signature Therapeutics R&D Efforts To Reduce Prescription Drug Abuse
3. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
4. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
5. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):